Impact of low‐value medications on quality of life, hospitalization and costs – A longitudinal analysis of patients living with dementia

• DOI: 10.1002/alz.13012
• Publication Date: 2023-03-11T11:14:12Z
• Authors: Moritz Platen; Steffen Flessa; Stefan Teipel; Anika Rädke; Annelie Scharf; Wiebke Mohr; Maresa Buchholz; Wolfgang Hoffmann; Bernhard Michalowsky
• Keywords: Longitudinal Study

This study aimed to analyze the impact of low-value medications (Lvm), that is, unlikely benefit patients but cause harm, on patient-centered outcomes over 24 months.This longitudinal analysis was based baseline, 12 and months follow-up data 352 with dementia. The Lvm health-related quality life (HRQoL), hospitalizations, health care costs were assessed using multiple panel-specific regression models.Over months, 182 (52%) received at least once 56 (16%) continuously. significantly increased risk hospitalization by 49% (odds ratio, confidence interval [CI] 95% 1.06-2.09; p = 0.022), €6810 (CI -707€-14,27€; 0.076), reduced patients' HRQoL (b -1.55; CI -2.76 -0.35; 0.011).More than every second patient Lvm, negatively impacting patient-reported HRQoL, costs. Innovative approaches are needed encourage prescribers avoid replace in dementia care.Over more (Lvm). physical, psychological, financial outcomes. Appropriate measures change prescription behaviors.